Dasatinib and Mifepristone: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Mifepristone
Dasatinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased dasatinib exposure and an increased risk of QT interval prolongation
Interaction Deep Dive
Coadministration of miFEPRIStone (strong CYP3A4 inhibitor) (Korlym®) and dasatinib (CYP3A4 substrates with NTI) is contraindicated as it may increase dasatinib exposure3. However, exert caution when miFEPRIStone (Mifeprex®) is coadministered with dasatinib (CYP3A4 substrates with NTI). Due to the slow elimination of miFEPRIStone from the body, such interaction may be observed for a prolonged period after its administration 4. If coadministered, then reduce dasatinib dose from 70 mg/day or 100 mg/day to 20 mg daily or from 140 mg/day to 40 mg daily. For patients on dasatinib 40 mg or 60 mg daily, stop dasatinib until miFEPRIStone is discontinued. If dasatinib is not tolerated following a dose reduction, then either discontinue miFEPRIStone or discontinue dasatinib until treatment with miFEPRIStone is stopped. Once therapy with miFEPRIStone is discontinued, allow a washout period of approximately 1 week before reinitiating dasatinib or increasing the dasatinib dose to the indicated dose. Concomitant use may also increase the risk of QT prolongation. Correct hypomagnesemia or hypokalemia before and during dasatinib therapy 21.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of dasatinib; additive QT interval prolongation
Literature reports
2 reports — tap to read
a) Following coadministration with a single dose of dasatinib 20 mg and ketoconazole (a strong CYP3A4 inhibitor) twice daily, the mean Cmax of dasatinib increased 4-fold and the mean AUC increased 5-fold 21.
b) In a drug interaction study, coadministration of miFEPRIStone 1200 mg once daily for 10 days and simvastatin (CYP3A4 substrate) 80 mg single dose, resulted in increased simvastatin AUC and Cmax by 10.40-fold and 7.02-fold, respectively. Also resulted in increased simvastatin acid AUC and Cmax by 15.7-fold and 18.20, respectively 3.
Common questions
Can I take Dasatinib and Mifepristone together?
Increased dasatinib exposure and an increased risk of QT interval prolongation Always confirm with your pharmacist or prescriber before making any change.
How serious is the Dasatinib and Mifepristone interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Dasatinib or Mifepristone need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Product Information: PHYRAGO oral tablets, dasatinib oral tablets. Nanocopoeia, LLC (per FDA), New Brighton, MN, 2023. DailyMed
- Product Information: SPRYCEL(R) oral tablets, dasatinib oral tablets. Bristol-Myers Squibb Company (per FDA), Princeton, NJ, 2023. DailyMed
- Product Information: KORLYM(R) oral tablets, mifepristone oral tablets. Corcept Therapeutics Incorporated (per Dailmed), Redwood City, CA, 2024. DailyMed
- Product Information: MIFEPREX(R) oral tablets, mifepristone oral tablets. Danco Laboratories, LLC (per FDA), New York, NY, 2023. DailyMed
Keep reading about Mifepristone
Keep reading about Dasatinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist